Por favor, use este identificador para citar o enlazar este ítem:
Tipo
ArtículoDerechos de autor
Acceso abierto
Objetivos de Desarrollo Sostenible
03 Saúde e Bem-EstarColecciones
- IOC - Artigos de Periódicos [12776]
Metadatos
Mostrar el registro completo del ítem
TIME TO FACE THE PROOFS: THE BCG MOREAU VACCINE PROMOTES SUPERIOR INFLAMMATORY CYTOKINE PROFILE IN VITRO WHEN COMPARED WITH RUSSIA, PASTEUR, AND DANISH STRAINS
Vacina CG
Citocina
Mycobacterium bovis BCG Moreau
Mycobacterium bovis BCG Rússia
Deformação
CG Vaccine
Strains
Cytokine
Mycobacterium bovis BCG Moreau
Mycobacterium bovis BCG Russia
Autor
Afiliación
Resumen en ingles
Tuberculosis (TB) has been a major public health problem worldwide, and the Bacillus Calmette–Guérin
(BCG) vaccine is the only available vaccine against this disease. The BCG vaccine is no longer a single
organism; it consists of diverse strains. The early-shared strains of the BCG vaccine are stronger immunostimulators
than the late-shared strains. In this study, we have employed a simple in vitro human model
to broadly evaluate the differences among four widely used BCG vaccines during the characterization of
strain-specific host immune responses. In general, the BCG Moreau vaccine generated a higher inflammatory
cytokine profile and lower TGF-β levels compared with the Russia, Pasteur, and Danish strains in
the context of early sensitization with TB; however, no changes were observed in the IL-23 levels between
infected and noninfected cultures. Unsurprisingly, the BCG vaccines provided different features, and the
variances among those strains may influence the activation of infected host cells, which ultimately leads
to distinct protective efficacy to tackle TB.
Palabras clave en portugues
TuberculoseVacina CG
Citocina
Mycobacterium bovis BCG Moreau
Mycobacterium bovis BCG Rússia
Deformação
Palabras clave en ingles
TuberculosisCG Vaccine
Strains
Cytokine
Mycobacterium bovis BCG Moreau
Mycobacterium bovis BCG Russia
Compartir